26 Jul 2018 – Destiny Pharma announces positive data from XF-73 Phase 1 skin irritation study
News
Thursday July 26, 2018
26 Jul 2018 – Destiny Pharma announces positive data from XF-73 Phase 1 skin irrit...
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma announces positive data from XF-73 Phase 1 skin irritation study Positive data supports product opportunities for XF-73 in dermal infection […]
Tuesday July 17, 2018
17 Jul 2018 – Research collaboration with Aston University to investigate new XF-p...
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma announces research collaboration with Aston University to investigate new XF-platform drug candidates Research to investigate potential antimicrobial candidates against biofilms […]
Destiny Pharma welcomes this significant PULL incentive which could be worth >$1 billion for qualifying new antibiotics on approval. Please see link to article below https://bit.ly/2ID2BtW